Kolon Life Science

Kolon Life Science Net Margin

The Net Profit Margin of Kolon Life Science (102940.KQ) as of Nov 3, 2026 is 11.94 %. In the previous year, Net Profit Margin was -57.68 % — a change of -120.71% (higher).

Net Margin

11.94 %

YoY

-120.71%

Last updated:

Net Profit Margin of Kolon Life Science is 2025 11.94 % . Net Profit Margin of Kolon Life Science was 2024 -57.68 % . It decreases by -120.71% higher compared to the previous year.

Kolon Life Science's net margin stands at 11.9%, up from -0.8% several years earlier.

The Kolon Life Science Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-38.20 KRW
Jan 1, 2019
-62.15 KRW
Jan 1, 2020
-33.38 KRW
Jan 1, 2021
-0.83 KRW
Jan 1, 2022
1.32 KRW
Jan 1, 2023
-24.65 KRW
Jan 1, 2024
-57.68 KRW
Jan 1, 2025
11.94 KRW
The Kolon Life Science Net Margin history
YEARNet MarginYoY
11.94 %-120.71%
-57.68 %+133.97%
-24.65 %-1,967.24%
1.32 %-258.91%
-0.83 %-97.51%
-33.38 %-46.30%
-62.15 %+62.69%
-38.20 %+3,114.24%
-1.19 %-114.85%
8.00 %+1,111.79%
0.66 %-85.27%
4.48 %+3,532.27%
0.12 %+38.72%
0.09 %-12.68%
0.10 %-5.69%
0.11 %+79.79%
0.06 %+36.35%
0.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kolon Life Science Stock analysis

What does Kolon Life Science do? KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment. The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space. KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options. Kolon Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kolon Life Science stock

Net Profit Margin of Kolon Life Science is 11.94 % in 2025.

Net Profit Margin of Kolon Life Science changed from -57.68 % to 11.94 %, representing a -120.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Kolon Life Science since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Kolon Life Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Kolon Life Science

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Kolon Life Science